Loading clinical trials...
Loading clinical trials...
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
Conditions
Interventions
Fostamatinib Disodium
Locations
55
United States
Arizona Oncology Associates
Tucson, Arizona, United States
Bleeding & Clotting Disorders Institute
Peoria, Illinois, United States
Horizon Oncology Research, Inc
Lafayette, Indiana, United States
Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York, United States
Weill Cornell Medicine
New York, New York, United States
Start Date
October 1, 2014
Primary Completion Date
June 2, 2020
Completion Date
June 2, 2020
Last Updated
December 11, 2023
NCT06722235
NCT04890041
NCT07426107
NCT07059910
NCT03866577
NCT00621894
Lead Sponsor
Rigel Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions